 | Up a level |
Journal Article
Carles, J., Alcaraz, A., Clarke, N. W., Conde, A., Heidenreich, A., Juarez, A., Maroto Rey, J. P., Puente, J., Hernandez-Medrano, I., Salcedo, I., Haddad, I., Munoz del Toro, J., Servan, A., Pissart, G., Casariego, J. and Fizazi, K. (2020). ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region). Ann. Oncol., 31. S. S549 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Chowdhury, S., Abida, W., Arranz Arija, J., Daugaard, G., Fizazi, K., Gez, E., Heidenreich, A., Joly Lobbedez, F., McDermott, R., Merseburger, A. S., Piulats Rodriguez, J. M., Sautois, B., Sridhar, S., Sternberg, C. N., Watkins, S., Simmons, A., Shetty, S., Golsorkhi, A., Ryan, C. J. and Scher, H. (2017). The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Chowdhury, S., Shore, N., Saad, F., Higano, C. S., Fizazi, K., Iversen, P., Miller, K., Heidenreich, A., Ueda, T., Kim, C. S., Phung, D., Krivoshik, A., Wang, F., Wu, K. and Tombal, B. (2016). Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K-P., Fizazi, K., Fossa, S., Germa-Lluch, J. R., Giannatempo, P., Gietema, J. A., Gillessen, S., Haugnes, H. S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M. A. S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondrus, D., Papachristofilou, A., Powles, T., Sohaib, A., Stahl, O., Tandstad, T., Toner, G. and Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann. Oncol., 29 (8). S. 1658 - 1687. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B. and Gillessen, S. (2020). Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 31 (9). S. 1119 - 1135. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Stenzl, A., Feyerabend, S., Syndikus, I., Sarosiek, T., Kuebler, H., Heidenreich, A., Cathomas, R., Gruellich, C., Loriot, Y., Perez Gracia, S. L., Gillessen, S., Klinkhardt, U., Schroeder, A., Schoenborn-Kellenberger, O., Reus, V., Koch, S. D., Hong, H. S., Seibel, T., Fizazi, K. and Gnad-Vogt, U. (2017). Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041